Stephens Investment Management Group LLC Sells 235,691 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Stephens Investment Management Group LLC lessened its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 14.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,345,402 shares of the specialty pharmaceutical company’s stock after selling 235,691 shares during the period. Stephens Investment Management Group LLC’s holdings in Supernus Pharmaceuticals were worth $64,297,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of the company. USA Financial Formulas bought a new stake in shares of Supernus Pharmaceuticals in the 3rd quarter valued at about $50,000. EverSource Wealth Advisors LLC acquired a new stake in Supernus Pharmaceuticals in the second quarter valued at approximately $51,000. Raymond James Financial Inc. purchased a new position in Supernus Pharmaceuticals in the second quarter worth $55,000. Osaic Holdings Inc. grew its holdings in Supernus Pharmaceuticals by 211.5% in the second quarter. Osaic Holdings Inc. now owns 1,956 shares of the specialty pharmaceutical company’s stock worth $63,000 after purchasing an additional 1,328 shares during the last quarter. Finally, GAMMA Investing LLC increased its position in shares of Supernus Pharmaceuticals by 116.7% during the second quarter. GAMMA Investing LLC now owns 2,861 shares of the specialty pharmaceutical company’s stock worth $90,000 after purchasing an additional 1,541 shares in the last quarter.

Insider Buying and Selling at Supernus Pharmaceuticals

In related news, VP Padmanabh P. Bhatt sold 710 shares of the business’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $44.44, for a total transaction of $31,552.40. Following the completion of the transaction, the vice president directly owned 14,508 shares in the company, valued at $644,735.52. The trade was a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Frank Mottola sold 20,000 shares of the company’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $50.41, for a total transaction of $1,008,200.00. Following the completion of the sale, the senior vice president directly owned 15,496 shares in the company, valued at approximately $781,153.36. The trade was a 56.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 8.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on SUPN shares. Bank of America initiated coverage on Supernus Pharmaceuticals in a research note on Wednesday, October 29th. They set a “buy” rating and a $65.00 target price on the stock. Stifel Nicolaus boosted their price target on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a “hold” rating in a research note on Friday, December 19th. Piper Sandler upgraded shares of Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $40.00 to $65.00 in a report on Thursday, October 9th. TD Cowen increased their price objective on shares of Supernus Pharmaceuticals from $45.00 to $60.00 and gave the company a “buy” rating in a research report on Thursday, October 23rd. Finally, Wall Street Zen raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $61.60.

Supernus Pharmaceuticals Stock Down 0.5%

Shares of NASDAQ:SUPN opened at $50.00 on Friday. Supernus Pharmaceuticals, Inc. has a 52-week low of $29.16 and a 52-week high of $57.65. The stock has a market cap of $2.87 billion, a price-to-earnings ratio of -147.05, a PEG ratio of 0.49 and a beta of 0.67. The business has a 50-day moving average price of $47.96 and a 200-day moving average price of $44.94.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 earnings per share for the quarter, missing the consensus estimate of $0.82 by ($0.36). Supernus Pharmaceuticals had a positive return on equity of 11.51% and a negative net margin of 2.81%.The business had revenue of $170.00 million during the quarter, compared to analyst estimates of $175.82 million. During the same quarter last year, the company posted $0.69 EPS. Supernus Pharmaceuticals’s quarterly revenue was up 9.3% compared to the same quarter last year. As a group, equities analysts anticipate that Supernus Pharmaceuticals, Inc. will post 2.38 EPS for the current fiscal year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.